```html

Quasi‑inflammatory Keratitis – A Comprehensive Patient Guide

Overview

Quasi‑inflammatory keratitis is a non‑infectious, immune‑mediated inflammation of the cornea that mimics classic infectious keratitis in appearance but lacks a pathogenic organism. The term “quasi‑inflammatory” reflects that the disease sits on a spectrum between purely inflammatory (e.g., autoimmune keratitis) and infectious forms (e.g., bacterial keratitis). The condition is most often seen as a complication of ocular surface disease, contact‑lens wear, or systemic autoimmune disorders.

• Who it affects: Adults aged 20–55 are most commonly diagnosed, with a slight female predominance (≈55%). However, cases have been reported in children with severe atopic disease.
• Prevalence: Exact epidemiologic data are limited because the condition is rare and often mis‑classified. Large ophthalmology centers in the United States report an incidence of ~0.5–1 case per 10,000 new corneal clinic visits, representing less than 0.1 % of all keratitis diagnoses.<sup>1</sup>
• Geography: More frequently reported in regions with high contact‑lens usage and in populations with a high prevalence of autoimmune disease (e.g., North America, Europe, East Asia).

Symptoms

Symptoms can be subtle at first and often overlap with other corneal conditions. The following list captures the most commonly reported complaints, together with brief descriptions.

• Eye pain or discomfort: Ranges from a mild gritty sensation to sharp, throbbing pain, often worsened by blinking.
• Redness (hyperemia): Diffuse or sectoral injection of the bulbar conjunctiva, commonly more prominent at the limbus.
• Photophobia: Heightened light sensitivity; patients may need to squint or wear sunglasses even indoors.
• Foreign‑body sensation: The feeling that something is stuck in the eye, despite no visible object.
• Tearing (epiphora): Excessive watery discharge, usually non‑purulent.
• Decreased visual acuity: Blurry vision that may fluctuate; the severity depends on the depth and location of stromal involvement.
• Dryness or gritty feeling: Frequently reported in patients with underlying dry‑eye disease.
• Mucus or mucoid discharge: Typically scant and non‑purulent, differentiating it from bacterial keratitis.
• Eye fatigue: After prolonged visual tasks, the eye may feel “heavy” or strained.

Causes and Risk Factors

Primary Etiologic Mechanisms

Quasi‑inflammatory keratitis is thought to arise from an exaggerated immune response at the corneal surface. The exact pathway varies, but key mechanisms include:

1. Autoimmune dysregulation: Disorders such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome can direct autoreactive T‑cells to corneal antigens.
2. Allergic hypersensitivity: Atopic keratoconjunctivitis and vernal keratoconjunctivitis produce cytokine storms that spill over onto the cornea.
3. Contact‑lens‑related micro‑trauma: Chronic hypoxia and mechanical rubbing disrupt epithelial integrity, exposing stromal antigens to immune cells.
4. Environmental irritants: Smoke, chemicals, or UV exposure can trigger a local inflammatory cascade.

Risk Factors

• Prolonged soft‑contact‑lens wear (>6 hours/day) or poor lens hygiene.
• Existing ocular surface disease (dry eye, meibomian gland dysfunction).
• Systemic autoimmune disease (RR ≈ 3.2‑fold higher risk).<sup>2</sup>
• History of prior corneal infection or surgery (e.g., LASIK, PK).
• Allergic eye disease (e.g., seasonal allergic conjunctivitis).
• Smoking or exposure to indoor air pollutants.
• Genetic predisposition to heightened inflammatory responses (certain HLA types).

Diagnosis

Because the presentation mimics infectious keratitis, a systematic approach is essential to rule out pathogens and to confirm an inflammatory etiology.

Clinical Examination

• Slit‑lamp biomicroscopy: Reveals superficial stromal infiltrates, often peripheral, with a well‑defined “feathery” border. There is usually minimal or no epithelial defect.
• Fluorescein staining: May show small punctate epithelial erosions but typically no large ulcer.
• Anterior segment optical coherence tomography (AS‑OCT): Provides high‑resolution cross‑sections to assess depth of stromal involvement.

Laboratory & Ancillary Tests

1. Corneal scrapings for cultures: Gram stain, bacterial, fungal, and Acanthamoeba cultures are performed to exclude infection. Negative results after 48‑72 hours support a non‑infectious cause.
2. Polymerase chain reaction (PCR): Rapid detection of viral DNA (e.g., HSV, VZV) when viral keratitis is a differential.
3. Serologic work‑up: ANA, RF, anti‑CCP, and specific autoantibodies when systemic autoimmune disease is suspected.
4. Tear film analysis: Osmolarity and inflammatory cytokine levels (IL‑1β, IL‑6) may be elevated in inflammatory keratitis.

Diagnostic Criteria (Proposed)

Diagnosis is generally made when all three criteria are met:

• Clinical picture compatible with corneal inflammation without a clear epithelial defect or ulcer.
• Negative microbiologic studies (culture & PCR) after appropriate incubation.
• Evidence of underlying inflammatory trigger (e.g., contact‑lens wear, autoimmune disease) or response to anti‑inflammatory therapy.

Treatment Options

Treatment aims to quell inflammation, protect the cornea, and address any underlying systemic condition.

Pharmacologic Therapy

• Topical corticosteroids: First‑line for rapid control. Typical regimen: prednisolone acetate 1 % q4‑6 h, tapering over 4‑6 weeks based on response. Monitor intra‑ocular pressure (IOP) weekly.
• Non‑steroidal anti‑inflammatory drops (NSAIDs): E.g., ketorolac 0.5 % or diclofenac 0.1 % for adjunct pain relief; avoid monotherapy as they are less potent than steroids.
• Topical immunomodulators: Cyclosporine A 0.05 % or tacrolimus 0.03 % for chronic cases, especially when associated with dry eye or allergic disease.
• Systemic immunosuppression: In refractory or autoimmune‑driven cases, oral prednisone (0.5 mg/kg) with a slow taper or steroid‑sparing agents (mycophenolate mofetil, azathioprine) may be indicated. Collaboration with a rheumatologist is recommended.
• Lubrication and barrier protection: Preservative‑free artificial tears q2‑4 h, hyaluronic acid gels, and therapeutic soft lenses (band‑age contact lens) to promote healing and reduce friction.

Procedural Interventions

• Therapeutic band‑age contact lens: Provides mechanical protection and promotes epithelial stability.
• Amniotic membrane transplantation (AMT): Considered for persistent epithelial defects or stromal thinning.
• Phototherapeutic keratectomy (PTK): In select chronic cases with superficial scarring to improve visual acuity.

Lifestyle and Supportive Measures

• Discontinue or replace contact lenses; use daily disposables if lenses are necessary.
• Implement a strict lens‑care regimen (hydrogen‑peroxide systems, regular case replacement).
• Treat concomitant dry‑eye disease with lid hygiene, warm compresses, and omega‑3 supplementation.
• Avoid exposure to tobacco smoke, dusty environments, and chemical fumes.

Living with Quasi‑inflammatory Keratitis

While the condition can be distressing, many patients achieve long‑term stability with proper management.

Daily Management Tips

• Medication adherence: Use a daily log or smartphone reminder to apply drops at the prescribed frequency.
• IOP checks: If you are on topical steroids, schedule an eye‑pressure check at least once a month for the first three months.
• Protective eyewear: Wear sunglasses with UV protection outdoors to reduce photic stress.
• Screen time breaks: Follow the 20‑20‑20 rule (every 20 min, look at something 20 ft away for 20 seconds) to lessen ocular surface strain.
• Hydration and diet: Adequate water intake and a diet rich in omega‑3 fatty acids (fish, flaxseed) support ocular surface health.
• Regular follow‑up: Visit your ophthalmologist every 3–6 months, or sooner if symptoms flare.

Emotional Well‑being

Chronic eye disease can cause anxiety about vision loss. Consider joining a support group, practicing stress‑reduction techniques (mindfulness, yoga), and discussing any emotional concerns with your health‑care provider.

Prevention

Because many triggers are modifiable, prevention focuses on hygiene, systemic health, and early detection.

• Contact‑lens hygiene: Follow manufacturer instructions, replace lenses and cases regularly, and avoid overnight wear unless approved.
• Manage underlying autoimmune disease: Keep rheumatology appointments, adhere to systemic therapy, and report ocular symptoms early.
• Control dry eye: Use preservative‑free lubricants, consider punctal plugs if recommended.
• Allergy control: Daily antihistamine or mast‑cell stabilizer eye drops during pollen season.
• Environmental protection: Wear safety glasses when working with chemicals or debris.

Complications

When left untreated or inadequately controlled, quasi‑inflammatory keratitis can lead to serious sequelae:

• Corneal scarring: Permanent stromal opacity causing visual impairment.
• Corneal thinning or ectasia: Risk of perforation in advanced cases.
• Secondary infection: Barrier disruption may predispose to bacterial or fungal superinfection.
• Elevated intra‑ocular pressure/glaucoma: Steroid‑induced hypertension in up to 20 % of patients on prolonged high‑dose topical steroids.<sup>3</sup>
• Reduced quality of life: Persistent photophobia, dry‑eye symptoms, and visual fluctuations can affect work and daily activities.

When to Seek Emergency Care

---

**References**

1. M. C. Khor et al., “Non‑infectious keratitis: Clinical features and treatment outcomes,” Ophthalmology Science, 2020. PMCID: PMC7071023
2. Centers for Disease Control and Prevention, “Autoimmune diseases,” 2023. CDC
3. Mayo Clinic, “Glaucoma – Treatment,” 2024. Mayo Clinic
4. American Academy of Ophthalmology, “Contact Lens–Related Complications,” 2022. AAO
5. World Health Organization, “Dry eye disease,” 2021. WHO

```